

Human FABP2 Sandwich ELISA Kit Datasheet

Please read it entirely before use

Catalogue Number: KE00263

Size: 96T

Sensitivity: 3.8 pg/mL

Range: 156.3-10000 pg/mL

Usage: For the quantitative detection of human FABP2 concentrations in serum, plasma, cell culture supernatant and cell

lysate.


This product is for research use only and not for use in human or animal therapeutic or diagnostic.

Table of content	page
1. Background	***** 3
2. Principle	***** 3
3. Required Materials	****** 3
4. Kit Components and Storage	4
5. Safety Notes	4
6. Sample Collection and Storage	***** 5
7. Regent Preparation	••••• 6
8. Assay Procedure Summary	••••• 7
9. Validation Data	8
9.1 Standard curve	8
9.2 Precision	••••• 10
9.3 Recovery	••••• 10
9.4 Sample values	11
9.5 Sensitivity	11
9.6 Linearity	12
10. References	

1. Background

FABP2, also known as the intestinal fatty acid binding protein (I-FABP), is expressed in the absorptive intestinal villus cells. It is mainly involved in intracellular transport and intestinal absorption of lipids. FABP2 has been considered a marker of mucosal injury and ischemia and serum I-FABP level is used as a tissue damage indicator.

2. Principle



Sandwich ELISA structure (HRP conjugated secondary antibody)

A capture antibody is pre-coated onto the bottom of wells which binds to analyte of interest. A detection antibody also binds to the analyte. Horseradish peroxidase (HRP)-conjugated secondary antibody binds to the detection antibody. TMB acts as the HRP substrate and the solution color will change from colorless to blue. A stop solution containing sulfuric acid turns solution yellow. The color intensity is proportional to the quantity of bound protein which is measurable at 450 nm with the correction wavelength set at 630 nm.

3. Required Materials

- 3.1 A microplate reader capable of measuring absorbance at 450 nm with the correction wavelength set at 630 nm.
- 3.2 Calibrated, adjustable precision pipettes and disposable plastic tips. A manifold multi-channel pipette is recommended for large assays.
- 3.3 Plate washer: automated or manual.
- 3.4 Absorbent paper towels.
- 3.5 Glass or plastic tubes to prepare standard and sample dilutions.
- 3.6 Beakers and graduated cylinders.
- 3.7 Log-log or semi-log graph paper or computer and software for ELISA data analysis. A four-parameter logistic (4-PL) curve-fit is recommended.

4. Kit Components and Storage

Microplate - antibody coated 96-well microplate (8 well × 12 strips)	1 plate	Unopened Kit:
Protein standard - 20000 pg/bottle; lyophilized	2 bottles	·
Detection Antibody (100×) - 120 μL/vial*	1 vial	Store at 2-8°C for 6 months or -
HRP-conjugated antibody (100×) - 120 µL/vial*	1 vial	20°C for 12 months.
Sample Diluent PT 4-eg - 30 mL/bottle. For human serum and plasma	1 bottle	Opened Kit:
Sample Diluent PT 4 - 30 mL/bottle. For cell culture supernatant	1 bottle	All reagents stored at 2-8°C for
Sample Diluent PT 3-ag - 30 mL/bottle. For cell lysate	1 bottle	3
Detection Diluent - 30 mL/bottle	1 bottle	7 days.
Wash Buffer Concentrate (20×) - 30 mL/bottle	1 bottle	Please use a new standard
Extraction Reagent - 30 mL/bottle	1 bottle	for each assay.
Tetramethylbenzidine Substrate (TMB) - 12 mL/bottle		
Stop Solution - 12 mL/bottle	1 bottle	
Plate Cover Seals	4 pieces	

^{*} Centrifugation immediately before use

5. Safety Notes

- 5.1 Avoid any skin and eye contact with Stop Solution and TMB. In case of contact, wash thoroughly with water.
- 5.2 Do not use the kit after the expiration date.
- 5.3 Do not mix or substitute reagents or materials from other kit lots or other sources.
- 5.4 Be sure to wear protective equipment such as gloves, masks and goggles during the experiment.
- 5.5 When using an automated plate washer, adding a 30 second soak period following the addition of Wash Buffer to improve assay precision

6. Sample Collection and Storage

- 6.1 Serum: Allow blood samples to clot for 30 minutes, followed by centrifugation for 15 minutes at 1000xg. Clear serum can be assayed immediately or aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.
- 6.2 Plasma: Use EDTA, heparin, or citrate as an anticoagulant for plasma collection. Centrifuge for 15 minutes at 1000xg within 30 minutes of collection. The plasma can be assayed immediately or aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.
- 6.3 Cell Culture Supernatant: Remove particulates by centrifugation for 5 minutes at 500xg and assay immediately or aliquot and store samples at \leq -20°C. Avoid repeated freeze-thaw cycles.
- 6.4 Cell Lysate:
- 1) Collect cells and wash by centrifuging at $500 \times g$ for 5 minutes before resuspension in pre-cooled PBS buffer. Perform this step three times.
- 2) Count cells and then discard the supernatant.
- 3) Add protease inhibitor cocktail to the Extraction Reagent to a final concentration immediately prior to performing cell lysis.
- 4) Add 1 mL of Extraction reagent (containing protease inhibitor cocktail) Per 1 x 107 cells, Incubate cell suspension on ice for 30 minutes, use ultrasound to treat the samples.
- 5) Centrifuge cell lysate at 10,000 x g for 5 minutes at 4°C.
- 6) Measure the concentration of total protein in cell lysate using BCA assay. Where possible, keep samples on ice to avoid protein degradation.


7. Regent Preparation

- 7.1 Wash Buffer (1X): If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have completely dissolved. Add 30 mL of Wash Buffer Concentrate(20X) to 570 mL deionized or distilled water to prepare 1X Wash Buffer.
- **7.2 Detection Antibody (1X):** Dilute 100X Detection Antibody 1:100 using Detection Diluent prior to assay. Suggested 1:100 dilution: $10 \,\mu$ L 100X Detection Antibody + 990 μ L Detection Diluent (Centrifuge the 100 X Detection Antibody solution for a few seconds prior to use).
- 7.3 HRP-conjugated antibody (1X): Dilute 100X HRP-conjugated antibody 1:100 using Detection Diluent prior to assay. Suggested 1:100 dilution: $10 \,\mu$ L 100X HRP-conjugated antibody + 990 μ L Detection Diluent (Centrifuge the 100X HRP-conjugated antibodyy solution for a few seconds prior to use).
- **7.4 Sample Dilution:** Different samples should be diluted with corresponding Sample Diluent, samples may require further dilution if the readout values are higher than the highest standard OD reading. Variations in sample collection, processing and storage may affect the results of the measurement.

Recommended Dilution for different sample types: 1:2 or 1:4 is recommended for human serum, plasma, cell culture supernatant and cell lysate.

7.5 Standard Serial Dilution:

For human serum and plasma samples, add 2 mL Sample Diluent PT 4-eg in protein standard; For cell culture supernatant, add 2 mL Sample Diluent PT 4 in protein standard; For cell lysate, add 2 mL Sample Diluent PT 3-ag in protein standard



Add # µL of Standard diluted in the previous step	_	500 μL					
# μL of Sample Diluent PT 4-eg, PT4 or PT 3-ag	2000 μL	500 μL					
	"sd7"	"sd6"	"sd5"	"sd4"	"sd3"	"sd2"	"sd1"

8. Assay Procedure Summary

Bring all reagents to room temperature before use (Detection antibody and HRP-conjugated antibody can be used immediately). To avoid cross-contamination, change pipette tips between additions of each standard level, between sample additions, and between reagent additions. Also, use separate reservoirs for each reagent.


- 8.1 Take out the required number of microplate strips and return excess strips to the foil pouch containing the drying reagent pack and reseal; store at 4°C immediately. Microplate strips should be used in one week.
- 8.2 Preset the layout of the microplate, including control group, standard group and sample group, add 100 µL of each standard and sample to the appropriate wells. (Make sure sample addition is uninterrupted and completed within 5 to 10 minutes, It is recommended to assay all standards, controls, and samples in duplicate).
- 8.3 Seal plate with cover seal, pressing it firmly onto top of microwells. Incubate the plate for 2 hours at 37°C.
- 8.4 Wash
- 1) Gently remove the cover seal. Discard the liquid from wells by aspirating or decanting. Remove any residual solution by tapping the plate a few times on fresh paper towels.
- 2) Wash 4 times with 1X Wash Buffer, using at least 350-400 μ L per well. Following the last wash, firmly tap plates on fresh towels 10 times to remove residual Wash Buffer. Avoid getting any towel fibers in the wells or wells drying out completely. 8.5 Add 100 μ L of 1X Detection Antibody solution (refer to Reagent Preparation7.2) to each well. Seal plate with cover seal and
- incubate for 1 hour at 37°C.
- 8.6 Repeat wash step in 8.4.
- $8.7 \text{ Add } 100 \,\mu\text{L}$ of 1X HRP-conjugated antibody solution (refer to Reagent Preparation7.3) to each well. Seal plate with cover seal and incubate the plate for 40 minutes at 37°C .
- 8.8 Repeat wash step in 8.4.
- 8.9 Signal development: Add 100 μ L of TMB substrate solution to each well, protected from light. Incubate for 15 to 20 minutes. Substrate Solution should remain colorless until added to the plate.
- 8.10 Quenching color development: Add 100 µL of Stop Solution to each well in the same order as addition of the TMB substrate. Mix by tapping the side of the plate gently. NB: Avoid skin and eye contact with the Stop solution.
- 8.11 Read results: Immediately after adding Stop solution read the absorbance on a microplate reader at a wavelength of 450 nm. If possible, perform a double wavelength readout (450 nm and 630 nm).
- 8.12 Data analysis: Calculate the average of the duplicate readings (OD value) for each standard and sample, and subtract the average of the zero standard absorbance. Construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis, use four-parameter logistic curve- fit (4-PL) analysis to do this. If the samples have been diluted, the OD readout from the standard curve must be multiplied by the dilution factor used.


Step	Reagent	Volume	Incubation	Wash	Notes
1	Standard and Samples	100 µL	120 min	4 times	Cover Wells incubate at 37°C
2	Diluent Antibody Solution	100 µL	60 min	4 times	Cover Wells incubate at 37°C
3	Diluent HRP Solution	100 µL	40 min	4 times	Cover Wells incubate at 37°C
4	TMB Substrate	100 µL	15-20 min	Do not wash	Incubate in the dark at 37°C
5	Stop Solution	100 µL	0 min	Do not wash	-
6	Read plate at 450 nm and 630 nm immediately after adding Stop solution. DO NOT exceed 5 minutes.				


9. Validation Data

9.1 Standard curve

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.







(pg/mL)	0.D	Average	Corrected
0	0.049 0.048	0.049	-
156.3	0.16 0.152	0.156	0.1075
312.5	0.26 0.246	0.253	0.2045
625	0.442 0.43	0.436	0.3875
1250	0.736 0.737	0.737	0.688
2500	1.245 1.264	1.255	1.206
5000	1.769 1.735	1.752	1.7035
10000	2.131 2.145	2.138	2.0895

(pg/mL)	0.D	Average	Corrected
0	0.081 0.082	0.082	1
156.3	0.249 0.235	0.242	0.1605
312.5	0.415 0.377	0.396	0.3145
625	0.687 0.634	0.661	0.579
1250	1.143 1.06	1.102	1.02
2500	1.684 1.595	1.640	1.558
5000	2.202 2.14	2.171	2.0895
10000	2.471 2.497	2.484	2.4025

(pg/mL)	O.D	Average	Corrected
0	0.076 0.075	0.076	-
156.3	0.147 0.158	0.153	0.077
312.5	0.223 0.237	0.230	0.1545
625	0.349 0.376	0.363	0.287
1250	0.585 0.604	0.595	0.519
2500	0.975 1.014	0.995	0.919
5000	1.513 1.566	1.540	1.464
10000	2.053 2.098	2.076	2

9.2 Precision

Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested 20 times on one plate to assess intra-assay precision.

Inter-assay Precision (Precision between assays) Three samples of known concentration were tested in 24 separate assays to assess inter-assay precision.

Intra-assay Precision						
Sample	n	Mean (pg/mL)	SD	CV%		
1	20	4,105.7	213.2	5.2		
2	20	990.7	27.3	2.8		
3	20	252.6	8.9	3.5		

Inter-assay Precision						
Sample	n	Mean (pg/mL)	SD	CV%		
1	24	4,412.0	271.2	6.1		
2	24	1022.1	61.0	5.9		
3	24	251.9	8.7	3.5		

9.3 Recovery

The recovery of human FABP2 spiked to three different levels throughout the range of the assay in various matrices was evaluated.

Sample Type		Average% of Expected	Range (%)
Human plasma	1:2	109	90-123
Папап разпа	1:4	101	96-109
Cell culture supernatant	1:2	101	83-110
cett cutture supernatant	1:4	99	90-108
Cell lysate	1:2	96	89-103
Cett tysate	1:4	105	92-116

9.4 Sample values

Human serum/plasma -samples from healthy volunteers were evaluated for human FABP2 in this assay. No medical histories were available for the donors used in this study.

Sample Type	Mean (pg/mL)	Range (pg/mL)
Human serum (n=8)	2,899.5	1,099.3-5,057.3
Human plasma (n=8)	1,566.0	664-2,309.7

Cell culture supernatant-Human peripheral blood mononuclear cells PBMC (1 x 10^6 cells/mL) were cultured in RPMI-1640 supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 μ g/mL streptomycin sulfate. Cells were stimulated with 10 μ g/mL PHA. Aliquots of the cell culture supernatant was removed on days 1 and 3,assayed for levels of human FABP2. No detectable levels were observed.

Cell lysate

Cell Type	FABP2 (pg/mL)	Total protein (mg/mL)
HT-29	603.3	10.3

9.5 Sensitivity

The minimum detectable dose of human FABP2 is 3.8 pg/mL. This was determined by adding two standard deviations to the concentration corresponding to the mean O.D. of 20 zero standard replicates.

9.6 Linearity

To assess the linearity of the assay, Cell culture supernatant was spiked with high concentrations of human FABP2 and diluted with the appropriate Sample Diluent to produce samples with values within the dynamic range of the assay. Human plasma and cell lysate were diluted with the appropriate Sample Diluent to produce samples with values within the dynamic range of the assay.

		Human plasma (Sample Diluent PT 4-eg)	Cell culturte supernatant (Sample Diluent PT 4)	Cell lysate (Sample Diluent PT 3-ag)
1:2	Average% of Expected	100	95	100
	Range (%)	-	90-98	-
1:4	Average% of Expected	119	93	90
	Range (%)	114-123	89-94	74-102
1:8	Average% of Expected	123	98	114
	Range (%)	117-128	97-100	114-114
1:16	Average% of Expected	112	102	
	Range (%)	103-125	97-106	

10. References

- 1. Murat Sarikaya. et al. (2015) Clin Lab. 2015;61(1-2):87-91. (PMID: 25807642)
- 2. Takeshi Kitai. et al. (2017) Clin Biochem. 2017 Jun;50(9):491-495. (PMID: 28232029)